myhc i  (Developmental Studies Hybridoma Bank)

Journal: medRxiv

Article Title: Single-Nucleus to Whole Body Phenotyping Reveals Neuromuscular Impairment and Preserved Exercise Adaptations in Long-Term Pediatric HSCT Survivors >10 years after treatment

doi: 10.64898/2026.04.24.26351644

Figure Lengend Snippet: (A) Representative magnetic resonance imaging (MRI) of the thigh and quadriceps muscle cross-sectional area (CSA) assessed by MRI (controls: n = 17; HSCT: n = 11). (B) Representative DXA scan and whole-body, and leg, lean mass assessed by DXA (controls: n = 27; HSCT: n = 17). (C) Whole-body bone mineral density and Z-scores assessed by DXA (controls: n = 27; HSCT: n = 17). (D) Isometric maximal voluntary contraction (MVC) measured by dynamometry, presented as Isometric MVC and Specific force (normalized to body weight) (controls: n = 28; HSCT: n = 18). Rate of force development (RFD) was also measured by dynamometry (controls: n = 11; HSCT: n = 7). (E) Physical function assessed using the 30-s chair-stand test, timed up-and-go test, and 6-min walk test (controls: n = 17; HSCT: n = 11). F-K. Data from muscle biopsy immunofluorescence, analyzed by two-way repeated-measures ANOVA with factors Group and Sex. Data are displayed as individual values with mean ± SD. Men are represented by circles, women by squares (controls: n = 26; HSCT: n = 16). (F) Muscle biopsy cross-section stained by immunofluorescence with the basement membrane marker laminin, delineating the muscle fiber borders, and type I myosin heavy chain (MyHC I). The unstained (black) fibers were designated type II fibers. Scale bar = 100 μm. Such images were used to calculate fiber type-specific data for G) fiber type distribution (proportion and relative area), H) shape factor index, I) fiber cross-sectional area (CSA), J) myonuclear content, K) myonuclear domain size. A-E. Data were analyzed with unpaired two-tailed t-tests.

Article Snippet: For fiber type–specific morphology and fiber type distribution, sections were stained with MyHC I (BA.D5; DSHB) and laminin (L9393; Sigma-Aldrich).

Techniques: Magnetic Resonance Imaging, Immunofluorescence, Staining, Membrane, Marker, Two Tailed Test

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF-F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD206 (Bio-Rad, MCA2387, 1:50), and laminin (Abcam, ab7463, 1:200).

Techniques: Immunofluorescence, Staining, Comparison

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Force-frequency curves showing maximal isometric tetanic force generated by the TA muscle in situ at day 14 post-injury. B: Total area under the force-frequency curve (absolute muscle strength). C-D: Specific force-frequency curves ( C ) and specific force-frequency area under the curve ( D ) (relative muscle strength) normalized to muscle size. E: Representative histological and immunofluorescence images of muscle cross-sections. Top: H & E staining; Middle: Actin (red), DAPI (blue), and Laminin (LAM, white); Bottom: Fiber type staining for type I (blue), type IIA (green), type IIX (black), and type IIX (red), and laminin (white). F-H: Quantification of regenerative maturation markers including the percentage of centrally nucleated myofibers ( F ), fibers with ≥2 central nuclei ( G ), and fibers with ≥3 central nuclei ( H ). I-J: Mean myofiber cross-sectional area (CSA) ( I ) and muscle fiber type profile (I, IIA, IIX, IIB) ( J ). Data are presented as mean ± SEM. For force-frequency curves statistical significance was determined by two-way ANOVA followed by Holm-Šídák post hoc tests. * denotes p<0.05 vs. uninjured control mice (CON), # denotes p<0.05 vs. injured mice receiving VEH, and $ denotes p<0.05 vs. injured mice receiving ASA. For bar graphs, different letters indicate significant differences (p<0.05) by one-way ANOVA with Holm-Šídák post hoc tests.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF-F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD206 (Bio-Rad, MCA2387, 1:50), and laminin (Abcam, ab7463, 1:200).

Techniques: Generated, In Situ, Immunofluorescence, Staining, Control